Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + sintilimab + SOX
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
Apatinib + sintilimab + SOX is an investigational combination therapy for advanced gastric and gastroesophageal junction cancers, particularly in AFP-positive or HER2-negative subtypes. The regimen combines three agent types: - **Apatinib**: An oral small molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), which acts as an antiangiogenic targeted therapy. - **Sintilimab**: A monoclonal antibody targeting programmed cell death-1 (PD-1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune response. - **SOX regimen**: A standard chemotherapy protocol consisting of S-1 (an oral fluoropyrimidine derivative) and oxaliplatin (a platinum-based cytotoxic agent). This combination is being studied in phase II trials as a first-line or perioperative therapy for advanced gastric cancer, with evidence suggesting increased pathological response rates when compared to chemotherapy alone or chemotherapy plus PD-1 blockade. The synergy is based on simultaneous antiangiogenic, cytotoxic, and immune checkpoint inhibition mechanisms[1][3][4][6][7].
- Other names
- apatinib + sintilimab + S-1 + oxaliplatinNeoadjuvant apatinib combined with sintilimab and perioperative SOX
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on apatinib + sintilimab + SOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + sintilimab + SOX.